Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
Anavex Life Sciences Challenges the Basic Assumptions In Treating Alzheimer’s Disease
The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.
Kimberly Ha of BioPharm Insight Identifies Disruptive Trends and Technologies in Biotechnology
Kimberly Ha notes that many big pharma companies are partnering with academic institutions and that oncology, followed by neurology is one of the hottest areas in acquisitions
PLC Medical Systems Uses Revenue in the EU to Fund Phase III Development in the US
Mark Tauscher, President and CEO of PLC Medical Systems Inc., discusses the company’s product RenalGuard, an important tool for ridding the body of toxins.
Advaxis CEO Tom Moore Discovers A New Way To Fight Cancer
OneMedRadio interviewed Tom Moore, CEO and Chairman of the Board of Directors of Advaxis [OTC:ADXS]. He discusses the company’s novel immunotherapy technology.
Verisante Technologies Detects Skin Cancer in Less Than A Second
OneMedRadio interviewed Thomas Braun, CEO of Verisante Technologies [CVE:VRS], a medical device company committed to commercializing innovative systems for the early detection of cancer.
ThermoGenesis Sees Explosive Growth Opportunities in Stem Cells
Mel Engle, CEO of ThermoGenesis [NASDAQ: KOOL] recently discussed with OneMedRadio, the company’s stem cell products and FDA approval that may have groundbreaking implications for the stem cell market.
